MyFinsight
Home
Blog
About
Net income/(gain)
attributable to pfizer inc....
-$248M
(-108.52%↓ Y/Y)
Net income/(gain)
before allocation to...
-$237M
(-108.09%↓ Y/Y)
Less net income
attributable to...
$10M
(-44.44%↓ Y/Y)
Discontinued operationsnet
of tax
$8M
(-68.00%↓ Y/Y)
Income/(gain) from continuing
operations
-$246M
(-108.47%↓ Y/Y)
Provision/(benefit) for taxes on
income/(loss)
-$407M
(-388.65%↓ Y/Y)
Biopharma
Segment-Operating Segments
$14,661M
(2.49%↑ Y/Y)
Corporate Non Segment
$373M
(7.18%↑ Y/Y)
Income/(gain) from continuing
operations before...
-$653M
(-121.45%↓ Y/Y)
Total revenues
$15,034M
(2.60%↑ Y/Y)
Cost of sales
$4,092M
(8.31%↑ Y/Y)
Other
(income)/deductionsnet
-$3,716M
(-402.84%↓ Y/Y)
Selling, informational
and administrative...
$3,411M
(-0.12%↓ Y/Y)
Research and development
expenses
$2,809M
(13.17%↑ Y/Y)
Amortization of intangible
assets
$1,185M
(-2.15%↓ Y/Y)
Restructuring charges and
certain...
$457M
(2638.89%↑ Y/Y)
Acquired in-process
research and development...
$16M
(700.00%↑ Y/Y)
Back
Back
Income Statement
Pfizer_(2021)-svg
PFIZER INC (PFE)
Pfizer_(2021)-svg
PFIZER INC (PFE)
source: myfinsight.com